ArticleScientific reports2026
Evaluating valaciclovir, letermovir, and maribavir safety in first-trimester human placental development.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital cytomegalovirus (CMV) infection is the leading preventable cause of childhood disability, including sensorineural hearing loss and cerebral palsy in high-income countries. Early maternal treatment with valaciclovir has been shown to reduce fetal infection. However, newer, more potent anti-CMV medications such as letermovir and maribavir are not routinely used in pregnancy due to limited safety data. This study aimed to assess the effect of aciclovir (the active metabolite of valaciclovir), letermovir, and maribavir on cell viability, functionality, and key cell signalling pathways in first-trimester human placental tissue. First-trimester placental tissue was obtained from individuals undergoing surgical abortion for psychosocial indications at 9–13 weeks of gestation. The effect of anti-CMV medications on primary cytotrophoblast cell survival was measured using a standard cell viability assay. The effects of anti-CMV medication exposure on Wnt and epithelial-to-mesenchymal transition (EMT) signalling pathways were evaluated in placental explant cultures. Their impact on cellular proliferation and migration was assessed using placental outgrowth cultures. Exposure to physiological or supraphysiological levels of aciclovir, letermovir, or maribavir for 48 h did not significantly alter cytotrophoblast cell viability compared to vehicle-treated controls. Aciclovir did not significantly impact Wnt and EMT signalling gene expression in first-trimester placental explants; however, letermovir and maribavir induced significant gene dysregulation. None of the three anti-CMV medications altered first-trimester trophoblast proliferation or migration. These results provide reassuring data supporting the safety of maternal valaciclovir therapy in the first trimester. They may also inform the selection of newer anti-CMV medications for future clinical trials for use in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.